Skip to content
stoqly
en Β· USD

Appearance

Language

Currency

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 27, 2026.

Sign in

Acumen Pharmaceuticals, Inc.

ABOS Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2020–FY2025

Add to portfolio Download report
Today
0.4%
Previous close
$2.27
Market cap
$163M
P/E
β€”
Day range
$2.10 $2.37
52-week range
$1.55 $3.37

Last close Β· Oct 27, 2026

$2.26

+$0.06 (+2.73%) past year

Share price

Acumen Pharmaceuticals, Inc.

What Acumen Pharmaceuticals, Inc. does

ABOS Β· Biological Products, (No Diagnostic Substances)

From its latest annual report

No business description yet.

Filing details

Legal name
Acumen Pharmaceuticals, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K Β· Mar 26, 2026
Accession Β· CIK
0001628280-26-021413 Β· 0001576885

Earnings calendar Β· Acumen Pharmaceuticals, Inc.

Every quarter, companies publish how much they sold and earned. These are the days Acumen Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.

Next results

March 25, 2027

Thursday Β· in 149 days

Time
Before the market opens
Covers
Period ended Dec 31, 2026
Source
Stoqly estimate

Estimated from the same quarter last year. It will be replaced by the announced date once there is one.

See who else reports that week β†’
Date Results for Time Source
Oct 26, 2026 Period ended Sep 30, 2026 Before the market opens 8-K β†—
Aug 12, 2026 Q2 '26 Before the market opens 8-K β†—
May 12, 2026 Q1 '26 Before the market opens 8-K β†—
Mar 26, 2026 Q4 '25 Before the market opens 8-K β†—
Nov 12, 2025 Q3 '25 Before the market opens 8-K β†—
Aug 12, 2025 Q2 '25 Before the market opens 8-K β†—
May 13, 2025 Q1 '25 Before the market opens 8-K β†—
Mar 27, 2025 Q4 '24 Before the market opens 8-K β†—

From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.

KIRA’s summary AI analyst

Hi! I read Acumen Pharmaceuticals, Inc.’s latest annual report (fiscal 2025). Here is what stands out:

1 strength 3 to watch

Acumen Pharmaceuticals, Inc. in 30 seconds

Good So-so Weak

Weak

Does it make a profit?

βˆ’$121M

No. It lost money last year.

Weak

How healthy are the accounts?

1 / 7

Weak. It passes 1 of 7 health tests.

For information

How is the share priced?

β€”

No P/E: it made no profit over the last four quarters.

Rules of thumb on reported numbers. A starting point, not a recommendation.

Key numbers, fiscal 2025

Market cap Last close times the latest diluted share count, so it is approximate.
$163M
Oct 27 close
P/E Last close divided by diluted earnings per share over the last four quarters.
β€”
On βˆ’$1.62 EPS (TTM)

Revenue

Total sales reported in the income statement.

See the full section β†’

Operating margin

Operating income as a share of revenue.

See the full section β†’

Net income

Profit after all expenses, interest and tax.

KIRA Β· Acumen Pharmaceuticals, Inc. lost $121M in fiscal 2025.

See the full section β†’

Free cash flow

Cash from operations minus capital spending.

KIRA Β· Free cash flow was βˆ’$116M in fiscal 2025, β€” of revenue.

See the full section β†’

Return on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

See the full section β†’
Charts by

Sales and profit

Is it selling more, and how much does it keep?

Revenue and margins

Revenue

Margins, % of revenue

Gross Operating Net FCF

In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).

Net income and earnings per share

Loss periods are shown in red.

KIRA summarises the numbers

  • Acumen Pharmaceuticals, Inc. lost $121M in fiscal 2025.

Net income

Net income

Diluted EPS

Diluted EPS

In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.

Cash and shareholders

How much cash comes in, and where does it go?

Cash flow

Cash from operations minus capital spending.

KIRA summarises the numbers

  • Free cash flow was βˆ’$116M in fiscal 2025, β€” of revenue.

Free cash flow

Free cash flow

Cash from operations vs capital spending

Cash from operations Capital spending

Cash from operations vs capital spending

Cash from operations Capital spending

In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.

Dividends, buybacks and share count

Dividends and buybacks

Dividends Buybacks

Diluted shares outstanding (annual)

In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. β€œPlan” marks trades under a pre-arranged Rule 10b5-1 plan.

KIRA summarises the numbers

  • In the last 12 months, insiders sold $0.6M of shares on the open market and bought none.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.6M

9 insiders

Of sales under plans

86%

$0.5M

DateInsiderTradeSharesPriceValueFiling
Jun 17, 2026 Derrell PorterDirector Sold 13,040 $2.33 $0.0M Form 4
Jun 16, 2026 Derrell PorterDirector Sold 12,800 $2.33 $0.0M Form 4
Jun 15, 2026 Derrell PorterDirector Sold 6,460 $2.35 $0.0M Form 4
Jun 9, 2026 Nathan B FountainDirector Sold 6,400 $2.23 $0.0M Form 4
Mar 6, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 2,090 $3.26 $0.0M Form 4
Feb 27, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 9,406 $3.01 $0.0M Form 4
Jan 28, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 2,671 $3.00 $0.0M Form 4
Jan 26, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 15,085 $3.00 $0.0M Form 4
Jan 23, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 5,633 $1.90 $0.0M Form 4
Jan 22, 2026 Russell BartonChief Operating Officer Sold plan 462 $1.84 $0.0M Form 4
Jan 22, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 1,687 $1.86 $0.0M Form 4
Jan 22, 2026 Eric SiemersChief Medical Officer Sold plan 895 $1.82 $0.0M Form 4
Jan 22, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 1,054 $1.84 $0.0M Form 4
Jan 22, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 2,689 $1.88 $0.0M Form 4
Jan 21, 2026 Eric SiemersChief Medical Officer Sold plan 2,331 $1.80 $0.0M Form 4
Jan 21, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 2,247 $1.81 $0.0M Form 4
Jan 21, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 2,473 $1.81 $0.0M Form 4
Jan 21, 2026 Russell BartonChief Operating Officer Sold plan 2,315 $1.81 $0.0M Form 4
Jan 21, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 9,346 $1.81 $0.0M Form 4
Jan 12, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 8,548 $1.71 $0.0M Form 4
Jan 12, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 5,388 $1.73 $0.0M Form 4
Jan 9, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 5,200 $1.76 $0.0M Form 4
Jan 9, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 12,941 $1.76 $0.0M Form 4
Jan 8, 2026 Russell BartonChief Operating Officer Sold plan 3,530 $1.86 $0.0M Form 4
Jan 8, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 8,143 $1.82 $0.0M Form 4
Jan 8, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 36,911 $1.82 $0.1M Form 4
Jan 8, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 6,888 $1.82 $0.0M Form 4
Jan 8, 2026 James J. DohertyPresident and CDO Sold plan 6,467 $1.82 $0.0M Form 4
Jan 7, 2026 Russell BartonChief Operating Officer Sold plan 1,700 $1.99 $0.0M Form 4
Jan 7, 2026 Amy SchacterleChief Regulatory Officer Sold plan 1,097 $1.98 $0.0M Form 4
Jan 7, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 5,805 $2.00 $0.0M Form 4
Jan 7, 2026 James J. DohertyPresident and CDO Sold plan 1,700 $1.99 $0.0M Form 4
Jan 7, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 37,755 $1.99 $0.1M Form 4
Jan 7, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 11,770 $1.99 $0.0M Form 4
Jan 6, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 5,100 $1.97 $0.0M Form 4
Jan 6, 2026 Eric SiemersChief Medical Officer Sold plan 6,834 $1.97 $0.0M Form 4
Jan 6, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 5,102 $1.97 $0.0M Form 4
Jan 6, 2026 Russell BartonChief Operating Officer Sold plan 3,618 $1.97 $0.0M Form 4
Jan 6, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 10,898 $1.97 $0.0M Form 4
Jan 5, 2026 Matt ZugaCFO & Chief Business Officer Sold plan 4,000 $1.96 $0.0M Form 4
Jan 5, 2026 Daniel Joseph OConnellChief Executive Officer, Director Sold plan 4,649 $1.97 $0.0M Form 4
Jan 5, 2026 Russell BartonChief Operating Officer Sold plan 4,000 $1.96 $0.0M Form 4
Jan 5, 2026 Eric SiemersChief Medical Officer Sold plan 4,000 $1.96 $0.0M Form 4
Jan 5, 2026 Derek M MeisnerChief Legal Officer & Corp Sec Sold plan 4,000 $1.96 $0.0M Form 4

In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.

Financial health

Can it carry its debts, and how well does it use its money?

Balance sheet

Cash, debt and the ratios that show how comfortably Acumen Pharmaceuticals, Inc. can carry it.

KIRA summarises the numbers

  • Acumen Pharmaceuticals, Inc. has $85.7M more cash than debt.

Cash vs debt (incl. leases)

Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $194M$178M$244M$172M$117M
Debt incl. finance leases β€”$0.0M$30.7M$29.4M$31.2M
Debt / equity β€”0.0x0.1x0.2x0.4x
Interest coverage β€”β€”βˆ’105.2xβˆ’28.0xβˆ’29.3x
Current ratio 38.6x23.1x19.0x6.5x4.1x
Quick ratio 38.6x23.1x19.0x6.5x4.1x
Total assets $230M$197M$310M$239M$123M
Total liabilities $5.1M$7.8M$43.2M$57.2M$52.4M
Shareholders' equity $225M$189M$267M$182M$70.4M
Net debt (βˆ’ = net cash) β€”βˆ’$178Mβˆ’$213Mβˆ’$142Mβˆ’$85.7M

In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)

Return on capital Return on equity Return on assets

In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

KIRA summarises the numbers

  • Acumen Pharmaceuticals, Inc. passes 1 of 7 financial health tests (Piotroski F-score).

TestFY20FY21FY22FY23FY24FY25
Net income is positive βœ• βœ• βœ• βœ• βœ• βœ•
Cash from operations is positive βœ• βœ• βœ• βœ• βœ• βœ•
Return on assets rose β€” βœ• βœ“ βœ“ βœ• βœ•
Cash from operations exceeds net income βœ• βœ“ βœ“ βœ“ βœ“ βœ“
Debt fell relative to assets β€” β€” β€” βœ• βœ• βœ•
Current ratio rose β€” β€” βœ• βœ• βœ• βœ•
Share count didn't rise β€” βœ• βœ• βœ• βœ• βœ•
Gross margin rose β€” β€” β€” β€” β€” β€”
Revenue rose relative to assets β€” β€” β€” β€” β€” β€”
F-score β€” / 3β€” / 5β€” / 62 / 71 / 71 / 7
Accruals ratio 0.3%βˆ’60.2%βˆ’3.6%βˆ’3.7%βˆ’5.9%βˆ’3.2%
Altman Z'' β€”49.0726.767.77βˆ’0.17βˆ’12.29

In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.

All figures

Every number, year by year.

6 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV
Fiscal yearFY20FY21FY22FY23FY24FY25
Income statement
Research and development $8.0M $12.3M $32.4M $42.3M $93.8M $105M
Operating income βˆ’$7.9M βˆ’$19.6M βˆ’$45.2M βˆ’$61.1M βˆ’$114M βˆ’$124M
Interest expense β€” β€” $0.0M $0.6M $4.1M $4.2M
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Net income βˆ’$7.3M βˆ’$101M βˆ’$42.9M βˆ’$52.4M βˆ’$102M βˆ’$121M
Diluted EPS βˆ’$17.48 βˆ’$5.02 βˆ’$1.06 βˆ’$1.08 βˆ’$1.71 βˆ’$2.00
Diluted shares 0.00B 0.02B 0.04B 0.05B 0.06B 0.06B
Cash flow
Cash from operations βˆ’$7.5M βˆ’$18.0M βˆ’$35.2M βˆ’$43.1M βˆ’$86.2M βˆ’$116M
Capital expenditure β€” $0.0M $0.2M $0.0M $0.0M $0.1M
Free cash flow β€” βˆ’$18.0M βˆ’$35.3M βˆ’$43.1M βˆ’$86.2M βˆ’$116M
Depreciation and amortization β€” $0.0M $0.0M $0.1M $0.1M $0.1M
Stock-based compensation $0.2M $0.9M $3.1M $6.1M $9.6M $9.9M
Balance sheet
Cash and short-term investments $43.8M $194M $178M $244M $172M $117M
Total debt β€” β€” $0.0M $29.9M $29.4M $31.2M
Finance lease liabilities β€” β€” β€” $0.8M β€” β€”
Current assets $44.4M $199M $180M $247M $178M $122M
Current liabilities β€” $5.1M $7.8M $13.0M $27.6M $30.0M
Property and equipment, net β€” $0.0M $0.2M $0.1M $0.1M $0.1M
Total assets $44.4M $230M $197M $310M $239M $123M
Total liabilities $6.4M $5.1M $7.8M $43.2M $57.2M $52.4M
Preferred stock β€” $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity βˆ’$18.6M $225M $189M $267M $182M $70.4M
Returns
Return on capital β€” β€” βˆ’319.9% βˆ’90.5% βˆ’227.0% β€”
Return on capital employed β€” βˆ’8.7% βˆ’24.0% βˆ’20.6% βˆ’53.9% βˆ’133.4%
Return on equity β€” βˆ’97.4% βˆ’20.7% βˆ’23.0% βˆ’45.6% βˆ’96.2%
Return on assets βˆ’16.5% βˆ’73.2% βˆ’20.1% βˆ’20.7% βˆ’37.3% βˆ’67.1%
Return on tangible equity β€” βˆ’44.7% βˆ’22.7% βˆ’19.6% βˆ’56.3% βˆ’172.3%
Growth
Share count change β€” 4,685.9% 102.4% 19.7% 23.5% 0.9%
Financial health
Debt / equity β€” β€” 0.0x 0.1x 0.2x 0.4x
Interest coverage β€” β€” β€” βˆ’105.2x βˆ’28.0x βˆ’29.3x
Current ratio β€” 38.6x 23.1x 19.0x 6.5x 4.1x
Quick ratio β€” 38.6x 23.1x 19.0x 6.5x 4.1x
Quality scores
Piotroski F-score β€” β€” β€” 2.0 1.0 1.0
Altman Z'' β€” 49.1 26.8 7.8 βˆ’0.2 βˆ’12.3
Accruals ratio 0.3% βˆ’60.2% βˆ’3.6% βˆ’3.7% βˆ’5.9% βˆ’3.2%

In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.

Source: SEC EDGAR XBRL filings (CIK 0001576885). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β€” not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move Β· ↡ to open